Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Foresite Capital Management VI LLC (CIK 2013341) reported $460.3M across 16 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: CGON ($150.3M, 32.67%), ALMS ($93.6M, 20.33%), CNTA ($54.2M, 11.77%), CRVS ($26.8M, 5.82%), DNLI ($23.2M, 5.05%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | CGON | CG Oncology, Inc. | $150.3M | 32.67% | 2.2M | Hold |
| 2 | ALMS | ALUMIS INC. | $93.6M | 20.33% | 4.2M | Hold |
| 3 | CNTA | Centessa Pharmaceuticals plc | $54.2M | 11.77% | 1.4M | Hold |
| 4 | CRVS | Corvus Pharmaceuticals, Inc. | $26.8M | 5.82% | 1.8M | Added |
| 5 | DNLI | Denali Therapeutics Inc. | $23.2M | 5.05% | 1.2M | Added |
| 6 | AGIO | AGIOS PHARMACEUTICALS, INC. | $17.8M | 3.86% | 525,000 | Trimmed |
| 7 | VSTM | Verastem, Inc. | $16.7M | 3.62% | 3.1M | Added |
| 8 | KYMR | Kymera Therapeutics, Inc. | $12.2M | 2.65% | 146,332 | Hold |
| 9 | NERV | Minerva Neurosciences, Inc. | $12.0M | 2.60% | 2.0M | New |
| 10 | CLDX | Celldex Therapeutics, Inc. | $10.0M | 2.18% | 315,913 | New |
| 11 | AtaiBeckley Inc. | $9.7M | 2.12% | 2.8M | New | |
| 12 | HNGE | Hinge Health, Inc. | $8.5M | 1.85% | 220,400 | Added |
| 13 | CRNX | Crinetics Pharmaceuticals, Inc. | $7.7M | 1.67% | 212,010 | New |
| 14 | OKUR | OnKure Therapeutics, Inc. | $6.0M | 1.30% | 1.4M | New |
| 15 | JBIO | Jade Biosciences, Inc. | $4.5M | 0.98% | 320,000 | New |
| 16 | GHRS | GH Research PLC | $4.4M | 0.96% | 315,492 | New |
| 17 | ZURA | Zura Bio Ltd | $2.7M | 0.58% | 450,000 | New |
| 18 | NTRA | Natera, Inc. | $0 | 0.00% | 0 | Exited |
| 19 | RAPT | RAPT Therapeutics, Inc. | $0 | 0.00% | 0 | Exited |
| 20 | ATAI | Atai Beckley N.V. | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-03-31